Combination of immuno gene therapy &amp; chemotherapy for treatment of cancer &amp; hyperproliferative diseases

ABSTRACT

Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.

PRIORITY CLAIM

Priority of U.S. Provisional patent application Ser. No. 60/635,042filed on Dec. 9, 2004 is claimed.

FIELD OF THE INVENTION

This invention relates to pharmaceutical compositions comprising anucleic acid, a gene delivery polymer, and at least one adjunctivechemotherapeutic drug for the treatment of mammalian cancer orhyperproliferative disorders. This invention also relates to methods oftreating mammalian cancer or hyperproliferative disorders, said methodcomprising contacting cancer cells or any other hyperproliferative cellswith said compositions by intratumoral, intraperitoneal or systemicinjection.

BACKGROUND OF THE INVENTION

Cancer is the most common cause of death in many parts of the world andover 2.5 million cases of cancer are diagnosed globally every year.Recent advances in our understanding of the molecular biology of cancerhave shown that cancer is a genetic disease resulting in the abnormalproliferation of the affected cell. Therefore, cancer therapists are nowfocusing on therapeutic strategies that involve macromolecules carryinggenetic information, rather than a therapeutic protein itself, allowingfor the exogenously delivered genes to be expressed in the tumorenvironment. Gene therapy is believed to offer therapeutic benefits tocancer patients in a number of ways that are not possible withconventional approaches. Traditional small molecule drugs usuallyfunction by non-specific interaction with the cellular targets, produceundesirable side effects and do not treat the root cause of the disease.Protein drugs which have been introduced over the last several yearshave their own limitations due to their rapid degradation and high dosesthat are required which often leads to undesirable side effects. Genetherapy uses the body's own cellular machinery to produce sustainedtherapeutic levels of proteins in specific tissues and cells after asingle injection, thus providing a safe and effective method oftreatment with better patient compliance.

The commonly applied cancer gene therapy strategies includeimmunotherapy, cell ablation and anti-angiogenesis accomplished by 1)local, 2) loco-regional, or 3) systemic injection. Cancer immunotherapyis a potent approach to combat cancer by stimulating the immune systemagainst the cancer cells. Immunocytokines play an important role in thedevelopment of the host immune response by activation, maturation anddifferentiation of the immune cells. Several cytokines have been testedagainst a variety of cancers in human and in animal models of cancers.See Hum Gene Ther., 1998, vol. 9, 2223; Gene Ther. 1999, vol. 6, 833;Cancer Gene Ther. 2000, vol. 7, 1156; J. Control Rel. 2003, vol. 87,177; and Cancer Res., 2002, vol. 62, 4023. Interleukin 12 (IL-12) is animmunostimulatory cytokine that shows great promise in the treatment ofhuman cancer. See The Oncologist, 1996, vol. 1, 88. IL-12 is a 70-kDheterodimer consisting of two covalently linked chains, p35 and p40. Thebiological effects of IL-12 include the induction of IFN-γ productionboth by resting and activated CD4+ T cells, CD8+ T cells, and naturalkiller (NK) cells. IL-12 also enhances the proliferation of activated Tand NK cells, increases the lytic activity of NK/lymphokine-activatedkiller cells, and facilitates specific cytotoxic T lymphocyte (CTL)responses.

In animal models, recombinant IL-12 has been demonstrated to induceprofound T-cell mediated antitumor effects causing regression ofestablished tumors, followed by systemic immune memory. See TheOncologist, 1996, vol. 1, 88. However, systemic administration ofrecombinant IL-12 has resulted in dose limiting toxicity in severalexperimental trials and in an initial human trial. See Lab Invest.,1994, vol. 71, 862; Science, 1995, vol. 270, 908; J. Interferon CytokineRes., 1995, vol. 14, 335. Dose limiting toxicity was also observed withintraperitoneal administration of recombinant IL-12 in a recent humanclinical trial. Clin. Cancer Res., 2002, vol. 8, 3686. A gene deliveryapproach that can provide therapeutic levels of IL-12 locally at thetumor site would have the advantage of generating an anticancer responsewithout causing systemic toxicity.

Both viral and non-viral gene delivery systems have been used for IL-12gene delivery in animal models of cancer. The viral approach has seriouspractical limitations due to toxicity concerns mainly because of anincreased incidence of cancer and a strong immune reaction to viralantigens by the host system. There is considerable interest in thedevelopment of non-viral gene delivery systems due to their lessertoxicity. Using polyvinylpyrrolidone (PVP), a non-viral gene deliverysystem, for the delivery of IL-12 to treat renal carcinoma (Renca) andcolon cell carcinoma (CT26) has been demonstrated. See Gene Ther., 1999,vol. 6, 833. When tumors were subjected to this gene therapy, theydisplayed all the characteristics of IL-12 protein therapy, e.g., anincreased infiltration of NK cells, CD4 and CD8 T cells, coupled with anincreased expression of major histocompatibility complex (MHC) class Imolecules. IL-12 gene delivery was well tolerated and highly effectiveagainst both Renca and CT26 tumor bearing animals. Tumor rejecting micewere also protected from a subsequent rechallenge, suggesting thepresence of a long lasting systemic immunity. A functionalized and lesstoxic water soluble lipopolymer (WSLP) has been tested for delivery ofthe IL-12 gene to CT26 colon carcinoma tumors. See Mahato et al, Mol.Ther., 2001, vol. 4, 130. IL-12 plasmid (pIL-12) and WSLP (pIL-12/WSLP)treatment gave higher levels of intratumoral gene expression than nakedDNA.

Furthermore, secondary effects of the cytokine IL-12 production, namelyIFN-γ and nitric oxide (NO) levels were also higher in WSLP treatedtumors when compared with naked DNA. A single injection of pIL-12/WSLPcomplexes produced suboptimal effects on tumor growth and animalsurvival, while repeated delivery yielded better efficacy whichindicates insufficient delivery by the system. J. Control Release 2003,vol. 87, 177. Similarly, intratumoral injection of IL-12 plasmid inanother polymeric carrier, PAGA, produced only partial inhibition ofCT26 tumors. See Gene Ther., 2002, vol. 9, 1075. These results warrantthe need for more efficient delivery systems. Despite theirinsufficiencies in earlier preclinical trials, the excellent molecularflexibility of polymeric gene carriers allows for complex modificationand novel functionalization imperative for the development of moreefficient gene delivery systems.

It is widely recognized that employing a single treatment strategyagainst cancer is generally ineffective due to the multi-factorialnature of this disease. The combination of more than one drug tomaximize the anticancer response is being increasingly utilized. SeeGene Ther., 2000, vol. 11, 1852. It has been demonstrated that there isa synergistic relationship between IL-12 gene therapy and IFN-α genetherapy. Co-treatment of Renca tumors with these two genes led to 100%tumor rejection which was higher than that achieved by treatments witheither IL-12 (58%) or IFN-α (25%) alone. Similarly, CT26 tumors showed a50% rejection rate with combination gene therapy which was higher thanthe 17% and 0% rejection rate achieved from single treatments of IL-12and IFN-α, respectively. Tumors treated by combination therapy showedincreased tumor-infiltration of NK and CD8 T cells when compared totumors treated by single gene therapy. Gene transfer ofmethylguanine-DNA-methyltransferase (MGMT) into stem cells alongsidewith chemotherapy protected normal cells from chemotherapy and reducedchemotherapy systemic toxicity. Nature Reviews Cancer 2004, vol. 4, 296.

Furthermore, combination gene therapy increased the number of CD40molecules on antigen presenting cells (APCs) in the tumors to levelshigher than was achieved with single treatments. Increased upregulationof CD40 on APCs is associated with higher activation status for antigenpresentation. See Nature, 1998, vol. 393, 480; Nature, 1998, vol. 393,474; and Nature, 1998, vol. 393, 478. A similar increase was observed inthe levels of mRNA for the chemokines IP-10 and TCA-3. Combination genetherapy therefore synergistically enhanced the anti-tumor immunity andthis effect was found to be long lasting in tumor rechallenge studies.Similar combination gene therapy studies have been reported by othergroups. See Laryngoscope 2001, vol. 111, 815. Established tumors weretreated with pIFN-α/PVP, pIL-2/lipid, or pIL-12/PVP alone or acombination thereof. The pIFN-α/PVP combination compared with the othertwo therapies significantly increased the antitumor effects whencompared with single treatments. In another study utilizing the sametumor model, it has been demonstrated that combined treatment withpIL-12/PVP and pIL-2/lipid gave significantly higher anti-tumor effectswhen compared with single treatments. See Arch. Otolaryngol Head NeckSurg, 2001, vol. 127, 1319.

In another study, intratumoral injection of polyplexes of linearpolyethylenimine (PEI) with an anti-oncogene and somatostatin receptorsubtype 2 (sst2), produced a significant inhibition of growth ofpancreatic tumors and metastases to the liver. Curr Opin Biotechnol,2002, vol. 13, 128. The PEI-mediated delivery of sst2 in tumors led toincreased apoptosis and activation of the caspase-3 and poly(ADP-ribose)pathways. Sustained delivery of DNA/PEI polyplexes into solid tumorsproduced higher expression than achieved by bolus delivery. Gene Ther.,1999, vol. 10, 1659. Dendrimers were used for inhibition of pancreaticcarcinoma and hepatocellular carcinoma by intratumoral gene transfer ofFas-L and HSV-1 thymidine kinase, respectively. See Gene Ther., 2003,vol. 10, 434; and Gene Ther., 2000, vol. 7, 53.

Chemo-immunotherapy using cytotoxic drugs and cytokines offers a newapproach for improving the treatment of neoplastic diseases. Thetherapeutic efficacy of combinations of IL-12 proteins withcyclophosphamide, paclitaxel, cisplatin or doxorubicin has beeninvestigated in the murine L1210 leukemia model. See Int. J. Cancer,1998, vol. 77, 720. Treatment of L1210 leukemia with IL-12 or one of theabove chemotherapeutic agents given alone resulted in moderateantileukemic effects. Combination of IL-12 with cyclophosphamide orpaclitaxel produced no augmentation of antileukemic effects incomparison with these agents given alone. However, combination of IL-12with doxorubicin augmented the antileukemic effect, while combinationwith cisplatin had a moderate enhancing effect.

However, in murine melanoma MmB16 model the IL-12+ paclitaxelcombination was more effective than the individual therapies. CancerLett., 1999, vol. 147, 67. The antitumor efficacy of IL-12 protein incombination with adriamycin, cyclophosphamide, or 5-FU in MB-49 bladdercarcinoma and B16 melanoma has also been examined. See, Clin. CancerRes., 1997, vol. 3, 1661. In combination with chemotherapy, IL-12administration increased antitumor activity without causing additionaltoxicity. In mouse sarcoma MCA207 that is refractory to treatment byeither IL-12 or cyclophosphamide, combination of recombinant IL-12 andcyclophosphamide gave a better antitumor response than the individualtreatments. J. Immunol., 1998, vol. 160, 1369. In mouse mammary tumors,combination therapy comprising intravenous paclitaxil chemotherapy andintratumoral IL-12 gene therapy (IL-12/WSLP) was more efficacious thanthe individual therapies. See, Molecular Therapy, 2004, vol. 9, 829. Thebenefit of this combination therapy was dependent on the deliveryvehicle used for paclitaxel. The synergistic interaction betweenpaclitaxel and IL-12 gene therapy was observed when paclitaxel wasformulated in a polymeric formulation. In comparison, combination withCremophor EL (Taxol®), a widely used paclitaxel formulation for cancertherapy, was not synergistic, suggesting that the observed benefits wereformulation specific.

To achieve a desirable outcome from a combination approach involvinggene therapeutics, the selection of an appropriate gene delivery systemis important. The gene delivery system used in the aforementionedcombination experiments (Molecular Therapy, 2004, vol. 9, 829) is awater soluble lipopolymer, PEI-Cholesterol (WSLP). In the presentinvention, we describe the use of a novel class of polymeric carriers(PEG-PEI-Cholesterol) structurally distinct from WSLP in that itcontains a hydrophilic polymer designed to improve pharmacokinetics,safety and potency of the gene delivery system and membrane interactingligands (e.g., cholesterol) that are oriented in numerous geometricalconfigurations to promote transfection activity of anticancer geneseither alone or in combination with a chemotherapeutic agent. Thetransfection activity advantage of PPC compared to WSLP in tumor tissueis illustrated in FIG. 1 and FIG. 2.

The combination of either two chemotherapeutic agents or achemotherapeutic agent and a cytokine has been examined clinically.Although these combinations have produced greater tumor regression, thelong-range survival benefits are marginal and cytotoxicity has been aproblem. This is due to the inherent systemic toxicity associated withchemotherapy and recombinant protein therapy. New and more effectivecombinational approaches must be designed to improve future cancertherapy. In this present invention, we describe a novel combinationalapproach for treatment of cancer comprising a nucleic acid basedtherapeutic delivered with a polymeric carrier and at least onechemotherapeutic agent.

BRIEF SUMMARY OF THE INVENTION

This present invention provides pharmaceutical compositions comprising anucleic acid, a gene delivery polymer, and at least one pharmaceuticalagent for the treatment of cancer. In addition, the present inventionalso provides a method for inhibiting the growth and metastasis of tumorcells and improving survival in mammals by the in vivo administration ofpharmaceutical compositions comprising a nucleic acid, a gene deliverypolymer, and at least one pharmaceutical agent.

The nucleic acid is a member selected from the group consisting ofplasmid DNA, siRNA, sense RNA, antisense RNA, and ribozymes. The plasmidDNA is a gene expression system containing a DNA sequence which encodesfor an anticancer or anti-proliferative protein selected from the groupconsisting of interleukin-2, interleukin-4, interleukin-7,interleukin-12, interleukin-15, interferon-α, interferon-β,interferon-γ, colony stimulating factor, granulocyte-macrophagestimulating factor, anti-angiogenic agents, tumor suppressor genes,thymidine kinase, eNOS, iNOS, p53, p16, TNF-α, Fas-ligand, mutatedoncogenes, tumor antigens, viral antigens or bacterial antigens. Theplasmid DNA may also encode for an shRNA molecule designed to inhibitprotein(s) involved in the growth or maintenance of tumor cells or otherhyperproliferative cells. A plasmid DNA may simultaneously encode for atherapeutic protein and one or more shRNA. Furthermore, the nucleic acidof the said composition may also be a mixture of plasmid DNA andsynthetic RNA including sense RNA, antisense RNA or ribozymes.

The gene delivery polymer is a cationic polymer or a non-condensingpolymer. The cationic polymer is selected from the group comprisingpolylysine, polyethylenimine, functionalized derivatives ofpolyethylenimine (PEI), polypropylenimine, aminoglycoside-polyamine,dideoxy-diamino-b-cyclodextrin, spermine and spermidine. One example ofa cationic gene delivery polymer suitable for the present invention is aPEI derivative comprising a PEI backbone, a lipid, and a hydrophilicpolymer spacer wherein the lipid is directly bound to thepolyethylenimine backbone or covalently bound to the polyethylene glycolspacer, which in turn is bound, via a biocompatible bond, to the PEI.The cationic gene delivery polymer of the present invention may furthercomprise a targeting moiety including antibodies or antibody fragments,cell receptors, growth factor receptors, cytokine receptors, folate,transferrin, epidermal growth factor (EGF), insulin, asialoorosomucoid,mannose-6-phosphate (monocytes), mannose (macrophage, some B cells),Lewis^(X) and sialyl Lewis^(X) (endothelial cells), N-acetyllactosamine(T cells), galactose (colon carcinoma cells), and thrombomodulin (mouselung endothelial cells), fusogenic agents such as polymixin B andhemaglutinin HA2, lysosomotrophic agents, nucleus localization signals(NLS) such as T-antigen, and the like. Another gene delivery polymer isa non-condensing polymer selected from the group comprisingpolyvinylpyrrolidone, polyvinylalcohol, poly(lactide-co-glycolide)(PLGA) and triblock copolymers of PLGA and PEG. The gene deliverypolymer may also be a non-condensing polymer. Examples of suchnon-condensing polymers include polyvinyl pyrollidone, polyvinylalcohol, poloxamers, polyglutamate, gelatin, polyphosphoesters,silk-elastin-like hydrogels, agarose hydrogels, lipid microtubules,poly(lactide-co-glycolide) and polyethyleneglycol-linkedpoly(lactide-co-glycolide).

In one embodiment of the foregoing composition the pharmaceutical agentis a chemotherapeutic drug selected from the group consisting oftaxanes, platinums, adriamycins, cylcophosphamide, topotecan, carmustine(BCNU) or a combination thereof. Paclitaxel, carboplatin, topotecan,gemcitabine and any combination thereof are particularly preferred.

In another embodiment of the foregoing compositions the pharmaceuticalagent is an anti-cancer antibody selected from the group consisting ofCD20 antibody, HER2/neu antibody, anti-VEGF antibody, epidermal growthfactor receptor antibody and radioisotopic conjugates thereof.

This present invention also provides a method for treatment of mammaliancancer by intratumoral, intraperitoneal, intratracheal, intracranial orsystemic administration of pharmaceutical compositions comprising anucleic acid, a nucleic acid delivery polymer, and at least oneadjunctive chemotherapeutic drug. The mammalian cancer is selected froma group consisting of primary or metastasized tumors of ovary, breast,brain, head and neck, liver, lung, prostate, kidney, colon, pancreas,thyroid, urinary bladder, abdominal cavity, thoracic cavity and skin.The nucleic acid and gene delivery polymer is administered byintratumoral, intraperitoneal, intratracheal or oral or systemicadministration before or after the administration of the pharmaceuticalagents. For example, in some instances it is preferred to administer thenucleic acid (e.g., pIL-12 DNA/polymer) prior to the pharmaceuticalagent (e.g., chemotherapy), as this would potentially enhance tumorsensitivity to the pharmaceutical agent and boost the anti-cancerresponse. In another instance, it is preferred to give thepharmaceutical agent (e.g., chemotherapy) prior to gene delivery (e.g.,pIL-12/PPC) to allow the pharmaceutical agent to cause tumor destructionand release of tumor antigens later to be used by the therapeutic gene(e.g., pIL-12/polymer) for eliciting highly specific and robusttherapeutic response (e.g., immune response) against the target cancer.

The treatment of tumors with the said pharmaceutical composition(nucleic acid plus gene delivery polymer and one or morechemotherapeutic agents) results in tumor shrinkage and extension oflife span. The combination of gene therapy (nucleic acid and genedelivery polymers) with chemotherapy (chemotherapeutic agents) accordingto the method of the present invention produce additive and/orsynergistic efficacy. The efficacy of the method of this invention isdefined as but not limited to shrinkage in tumor size or reduction intumor density, an increase in lymphocyte count or increase in neutrophilcount or improvement in survival, or all of the above. In addition, thecombination of gene therapy (nucleic acid and gene delivery polymers)with chemotherapy (chemotherapeutic agents) according to the method ofthe present invention lowers the toxicity of the chemotherapeutic agentand reverses tumor resistance to chemotherapy. The toxicity herein isdefined as any treatment related adverse effects on clinical observationincluding but not limited to abnormal hematology or serum chemistry ororgan toxicity. Furthermore, the combination of gene therapy (nucleicacid and gene delivery polymers) with a suboptimal dose of chemotherapy(chemotherapeutic agents) according to the method of the presentinvention enhances the anticancer effect to a level equal to or higherthan that of achieved with the optimal dose of the chemotherapeuticagent but with lesser toxicity.

In the said combination therapy, the nucleic acid is a member selectedfrom the group consisting of plasmid DNA, siRNA, sense RNA, antisenseRNA, and ribozymes. The nucleic acid can be a plasmid-based geneexpression system containing a DNA sequence which encodes for ananticancer or anti-proliferative protein selected from the groupconsisting of interleukin-2, interleukin-4, interleukin-7,interleukin-12, interleukin-15, interferon-α, interferon-β,interferon-γ, colony stimulating factor, granulocyte-macrophagestimulating factor, anti-angiogenic agents, tumor suppressor genes,thymidine kinase, eNOS, iNOS, p53, p16, TNF-α, Fas-ligand, mutatedoncogenes, tumor antigens, viral antigens or bacterial antigens. Theplasmid DNA may also encode for an shRNA molecule designed to inhibitprotein(s) involved in the growth or maintenance of tumor cells or otherhyperproliferative cells. A plasmid DNA may simultaneously encode for atherapeutic protein and one or more shRNA molecules. Furthermore, thenucleic acid of the said composition may also be a mixture of plasmidDNA and synthetic RNA. The gene delivery polymer is a cationic polymeror a non-condensing polymer. The cationic polymer is selected from thegroup comprising polylysine, polyethylenimine, functionalizedderivatives of polyethylenimine, polypropylenimine,aminoglycoside-polyamine, dideoxy-diamino-b-cyclodextrin, spermine andspermidine. One example of a cationic gene delivery polymer suitable forthe present invention is a polyethylenimine derivative comprising apolyethylenimine (PEI) backbone, a lipid, and a polyethylene glycolspacer wherein the lipid is directly bound to the polyethyleniminebackbone or covalently bound to the polyethylene glycol spacer, which inturn is bound, via a biocompatible bond, to the PEI. The cationic genedelivery polymer of the present invention may further comprise atargeting moiety including antibodies or antibody fragments, cellreceptors, growth factor receptors, cytokine receptors, folate,transferrin, epidermal growth factor (EGF), insulin, asialoorosomucoid,mannose-6-phosphate (monocytes), mannose (macrophage, some B cells),Lewis^(X) and sialyl Lewis^(X) (endothelial cells), N-acetyllactosamine(T cells), galactose (colon carcinoma cells), and thrombomodulin (mouselung endothelial cells), fusogenic agents such as polymixin B andhemaglutinin HA2, lysosomotrophic agents, nucleus localization signals(NLS) such as T-antigen, and the like. The gene delivery polymer is anon-condensing polymer selected from the group comprisingpolyvinylpyrrolidone, polyvinylalcohol, poly(lactide-co-glycolide)(PLGA) and triblock copolymers of PLGA and PEG. The chemotherapeuticdrug is a member selected from the group consisting of texanes,platinums, adriamycins, cylcophosphamide, topotecan, carmustine (BCNU)or a combination thereof. Paclitaxel, carboplatin, topotecan,gemcitabine and any combination thereof are particularly preferred.

In another embodiment of the foregoing method the pharmaceutical agentis an anti-cancer antibody selected from the group consisting of CD20antibody, HER2/neu antibody, anti-VEGF antibody, epidermal growth factorreceptor antibody and radioisotopic conjugates thereof.

This present invention also provides a method for treatment of mammaliancancer or hyperproliferative disorders by intratumoral, intraperitoneal,intratracheal, intracranial or systemic administration of pharmaceuticalcompositions comprising a plasmid-based gene expression system and agene delivery polymer, without a chemotherapeutic drug. The mammaliancancer is selected from a group consisting of primary or metastasizedtumors of ovary, breast, brain, head and neck, thyroid, liver, lung,pancreas, intestine, spleen, prostate, kidney, urinary bladder, colon,and melanoma. Preferably, the nucleic acid is a plasmid-based geneexpression system containing a DNA sequence which encodes an anticanceror anti-proliferative protein selected from the group consisting ofinterleukin-2, interleukin-4, interleukin-7, interleukin-12,interleukin-15, interferon-α, interferon-β, interferon-γ, colonystimulating factor, granulocyte-macrophage stimulating factor,anti-angiogenic agents, tumor suppressor genes, thymidine kinase, eNOS,iNOS, p53, p16, TNF-α, Fas-ligand, mutated oncogenes, tumor antigens,viral antigens or bacterial antigens. The plasmid DNA may also encodefor an shRNA molecule designed to inhibit protein(s) involved in thegrowth or maintenance of tumor cells or other hyperproliferative cells.A plasmid DNA may simultaneously encode for a therapeutic protein andone or more shRNA molecules. Furthermore, the nucleic acid of the saidcomposition may also be a mixture of plasmid DNA and synthetic RNA.

The gene delivery polymer of the said composition is a cationic polymeror a non-condensing polymer. The cationic polymer is selected from thegroup comprising polyethylenimine, functionalized derivatives ofpolyethylenimine, polypropylenimine, aminoglycoside-polyamine,dideoxy-diamino-b-cyclodextrin, spermine and spermidine. One example ofa cationic polymer suitable for presentation is a polyethyleniminederivative comprising polyethylenimine (PEI), a lipid, and a hydrophilicpolymer spacer wherein the lipid is directly bound to thepolyethylenimine backbone or covalently bound to the hydrophilic polymerspacer, which in turn is bound via a biocompatible bond to the PEI. Thecationic polymer of the present invention may further comprise atargeting moiety including antibodies or antibody fragments, cellreceptors, growth factor receptors, cytokine receptors, folate,transferrin, epidermal growth factor (EGF), insulin, asialoorosomucoid,mannose-6-phosphate (monocytes), mannose (macrophage, some B cells),Lewis^(X) and sialyl Lewis^(X) (endothelial cells), N-acetyllactosamine(T cells), galactose (colon carcinoma cells), and thrombomodulin (mouselung endothelial cells), fusogenic agents such as polymixin B andhemaglutinin HA2, lysosomotrophic agents, nucleus localization signals(NLS) such as T-antigen, and the like. Another gene delivery polymer isa non-condensing polymer selected from the group comprisingpolyvinylpyrrolidone, polyvinylalcohol, poly(lactide-co-glycolide)(PLGA) and triblock copolymers of PLGA and PEG. The treatment of tumorswith the pharmaceutical composition (nucleic acid plus gene deliverypolymer and one or more chemotherapeutic agent) results in tumorshrinkage and extension of the life span.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the difference in the efficiency of gene transferbetween the gene delivery polymers PEG-PEI-Cholesterol (PPC) and a watersoluble lipopolymer, PEI-Chol (WSLP). The test polymers were complexedwith a luciferase plasmid and administered intratumorally into 4T1breast tumors. Luciferase expression was quantified in tumor tissues 24hours thereafter.

FIG. 2 illustrates the effect of increasing the PEG:PEI ratio inPEG-PEI-Chol on the efficiency of gene transfer into solid 4T1 tumors byintratumoral administration of plasmid/PPC complexes. The PPC polymer,synthesized at different PEG:PEI ratios, was complexed with a luciferaseplasmid and administered intratumorally into 4T1 breast tumors.Luciferase expression was quantified in tumor tissues 24 hoursthereafter.

FIG. 3 illustrates IL-12 gene transfer into solid breast tumors byintratumoral administration (A) and into peritoneal disseminated ovariantumors (ID8 tumors) by intraperitoneal injection (B) of pmIL-12/PPCcomplexes. PPC was complexed with a mouse IL-12 gene expressionplasmid(pmIL-12), and administered intratumorally into 4T1 breast tumorsand intraperitoneally into ID8 peritoneal tumor bearing mice. IL-12levels were quantified after 24 hours in 4T1 tumors and after 1, 2, 3and 7 days in the peritoneal ascites in ID8 tumor bearing animals.

FIG. 4 illustrates the time course of IFN-γ production followingintraperitoneal administration of pmIL-12/PPC. PPC was complexed with amouse IL-12 gene expression plasmid (pmIL-12), and administeredintraperitoneal into ID8 peritoneal tumor bearing mice. IFN-γ levelswere quantified in peritoneal ascites after 1, 2, 3 and 7 days.

FIG. 5 illustrates dose-dependent inhibition of peritoneal disseminatedovarian tumors by intraperitoneal administration of pmIL-12/PPCcomplexes. pmIL-12/PPC complexes prepared at various DNA doses wereadministered intraperitoneally into peritoneal disseminated ID8 tumorbearing mice. The animals were periodically weighed to assess theeffects of treatment on tumor burden, and survival data was recorded.

FIG. 6 illustrates improvement in the survival of peritonealdisseminated ovarian tumor bearing mice by intraperitonealadministration of pmIL-12/PPC complexes.

FIG. 7 illustrates improvement in the survival of peritonealdisseminated colorectal tumor bearing mice by intraperitonealadministration of pmIL-12/PPC complexes. pmIL-12/PPC complexes wereadministered intraperitoneally into the tumor bearing mice. The test andcontrol animals were monitored for survival.

FIG. 8 illustrates improvement in the survival of GL-261 glioma bearingmice by intratumoral administration of pmIL-12/PPC complexes.pmIL-12/PPC complexes were administered into the cranial cavity at thetime of tumor implantation. The test and control animals were monitoredfor survival.

FIG. 9 illustrates inhibition of subcutaneous squamous cell carcinoma byintratumoral administration of pmIL-12/PPC complexes. The pmIL-12/PPCcomplexes were administered intratumorally into subcutaneous SCCVIItumors 6-7 days after tumor implantation and the treatment was repeatedonce every week for a total of 4 weeks. To assess the treatmentefficacy, tumor size was measured periodically.

FIG. 10 illustrates inhibition of peritoneal disseminated ovarian tumorsby combination therapy comprising intraperitoneal pmIL-12/PPC andintravenous paclitaxil. The pmIL-12/PPC complexes were administered byintraperitoneal injection 21 days after the implantation of tumor cells.The pmIL-12/PPC treatment was repeated 7 days later. Paclitaxel wasadministered intravenously only once, the day before the first geneinjection. The test and control animals were monitored for survival.

FIG. 11 illustrates inhibition of peritoneal disseminated ID8 ovariantumors by combination therapy comprising intraperitoneal pmIL-12/PPC andgemcitabine chemotherapy. The tumor bearing mice were treated withintraperitoneal gemcitabine 14 days after tumor implantation and thetreatment was repeated once every week for a total of 4 treatments. Thefirst pmIL-12/PPC treatment was given 17 days after tumor implantationby intraperitoneal injection and repeated once every week for a total of4 treatments. The test and control animals were monitored for survival.

FIG. 12 illustrates inhibition of peritoneal disseminated ovarian tumorsby combination therapy comprising intraperitoneal pmIL-12/PPC andcarboplatin/paclitaxel chemotherapy. Chemotherapy treatment was started15 days after tumor implantation, carboplatin was given once every weekfor 4 weeks and Taxol was given once every two week for a total of twotreatments. The first pmIL-12/PPC treatment was given 18 days aftertumor implantation by intraperitoneal injection and repeated once everyweek for a total of 4 treatments. The test and control animals weremonitored for survival.

FIG. 13 illustrates inhibition of SCCVII tumors by intratumoraladministration of pmIL-12/PPC complexes and cyclophosphamidechemotherapy. pmIL-12/PPC complexes were administered intratumorallyinto subcutaneous SCCVII tumors 6-7 days after tumor implantation andthe treatment was repeated once every week for a total of 4 weeks.Cytoxan was administered intravenously one day before gene injection andrepeated after 14 days. To assess treatment efficacy, tumor size wasmeasured periodically.

FIG. 14 illustrates inhibition of GL261 glioma by intratumoraladministration of pmIL-12/PPC complexes and BCNU chemotherapy.pmIL-12/PPC complexes were administered into the cranial cavity at thetime of tumor implantation. BCNU was administered as a Gliadel wafer 5days after tumor implantation. The test and control animals weremonitored for survival.

FIG. 15 illustrates that addition of IL-12/PPC gene therapy to low dosecarboplatin/paclitaxel chemotherapy does not increase toxicity. Incomparison, treatment with high dose carboplatin/paclitaxel chemotherapyled to a 30% rate of treatment-related deaths. Chemotherapy treatmentwas started 15 days after tumor implantation, carboplatin was given onceevery week for 4 weeks and Taxol was given once every two week for atotal of two treatments. The first pmIL-12/PPC treatment was given 18days after tumor implantation by intraperitoneal injection and repeatedonce every week for a total of 4 treatments. The entire treatment cyclewas repeated three times. The test and control animals were monitoredfor survival.

DETAILED DESCRIPTION

Before the present composition and method for delivery of a bioactiveagent are disclosed and described, it is to be understood that thisinvention is not limited to the particular configurations, processsteps, and materials disclosed herein as such configurations, processsteps, and materials may vary somewhat. It is also to be understood thatthe terminology employed herein is used for the purpose of describingparticular embodiments only and is not intended to be limiting since thescope of the present invention will be limited only by the appendedclaims and equivalents thereof.

It must be noted that, as used in this specification and the appendedclaims, the singular forms “a,” “an,” and “the” include plural referentsunless the context clearly dictates otherwise. Thus, for example,reference to a polymer containing “a disulfide link” includes referenceto two or more of such disulfide links, reference to “a ligand” includesreference to one or more of such ligands, and reference to “a drug”includes reference to two or more of such drugs.

In describing and claiming the present invention, the followingterminology will be used in accordance with the definitions set outbelow.

“Transfecting” or “transfection” shall mean transport of nucleic acidsfrom the environment external to a cell to the internal cellularenvironment, with particular reference to the cytoplasm and/or cellnucleus. Without being bound by any particular theory, it is to beunderstood that nucleic acids may be delivered to cells either afterbeing encapsulated within or adhering to one or more cationicpolymer/nucleic acid complexes or being entrained therewith. Particulartransfecting instances deliver a nucleic acid to a cell nucleus. Nucleicacids include DNA and RNA as well as synthetic congeners thereof. Suchnucleic acids include missense, antisense, nonsense, as well as proteinproducing nucleotides, on and off and rate regulatory nucleotides thatcontrol protein, peptide, and nucleic acid production. In particular,but not limited to, they can be genomic DNA, cDNA, mRNA, tRNA, rRNA,hybrid sequences or synthetic or semi-synthetic sequences, and ofnatural or artificial origin. In addition, the nucleic acid can bevariable in size, ranging from oligonucleotides to chromosomes. Thesenucleic acids may be of human, animal, vegetable, bacterial, viral, orsynthetic origin. They may be obtained by any technique known to aperson skilled in the art.

As used herein, the term “pharmaceutical agent” or “drug” or any othersimilar term means any chemical or biological material or compoundsuitable for administration by the methods previously known in the artand/or by the methods taught in the present invention, which induce adesired biological or pharmacological effect, which may include but arenot limited to (1) having a prophylactic effect on the organism andpreventing an undesired biological effect such as preventing aninfection, (2) alleviating a condition caused by a disease, for example,alleviating pain or inflammation caused as a result of disease, and/or(3) either alleviating, reducing, or completely eliminating a diseasefrom the organism. The effect may be local, such as providing for alocal anesthetic effect, or it may be systemic.

This invention is not drawn to novel drugs or to new classes ofbioactive agents per se. Rather it is drawn to biocompatible cationiccopolymer compositions and methods of using such compositions for thedelivery of genes or other bioactive agents that exist in the state ofthe art or that may later be established as active agents and that aresuitable for delivery by the present invention. Such substances includebroad classes of compounds normally delivered into the body. In general,this includes but is not limited to: nucleic acids, such as DNA, RNA,and oligonucleotides, anti-infective such as antibiotics and antiviralagents; analgesics and analgesic combinations; anorexics;antihelminthics; antiarthritics; antiasthmatic agents; anticonvulsants;antidepressants; antidiabetic agents; antidiarrheals; antihistamines;antiinflammatory agents; antimigraine preparations; antinauseants;antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics;antipyretics; antispasmodics; anticholinergics; sympathomimetics;xanthine derivatives; cardiovascular preparations including potassium,calcium channel blockers, beta-blockers, alpha-blockers, andantiarrhythmics; antihypertensives; diuretics and antidiuretics;vasodilators including general, coronary, peripheral and cerebral;central nervous system stimulants; vasoconstrictors; cough and coldpreparations, including decongestants; hormones such as estradiol andother steroids including corticosteroids; hypnotics; immunosuppressives;muscle relaxants; parasympatholytics; psychostimulants; sedatives; andtranquilizers. By the method of the present invention, drugs in allforms, e.g. ionized, nonionized, free base, acid addition salt, and thelike may be delivered, as can drugs of either high or low molecularweight. The only limitation to the genus or species of bioactive agentto be delivered is that of functionality which can be readily determinedby routine experimentation.

As used herein, the term “biocompatible” or “biodegradation” is definedas the conversion of materials into less complex intermediates or endproducts by solubilization hydrolysis, or by the action of biologicallyformed entities which can be enzymes and other products of the organism.

As used herein, “effective amount” means the amount of a nucleic acid ora bioactive agent that is sufficient to provide the desired local orsystemic effect and performance at a reasonable risk/benefit ratio aswould attend any medical treatment.

As used herein, “peptide” means peptides of any length and includesproteins. The terms “polypeptide” and “oligopeptide” are used hereinwithout any particular intended size limitation, unless a particularsize is otherwise stated. Typical of peptides that can be utilized arethose selected from the group consisting of oxytocin, vasopressin,adrenocorticotrophic hormone, epidermal growth factor, prolactin,luliberin or luteinising hormone releasing hormone, growth hormone,growth hormone releasing factor, insulin, somatostatin, glucagon,interferon, gastrin, tetragastrin, pentagastrin, urogastroine, secretin,calcitonin, enkephalins, endorphins, angiotensins, renin, bradykinin,bacitracins, polymixins, colistins, tyrocidin, gramicidines, andsynthetic analogues, modifications and pharmacologically activefragments thereof, monoclonal antibodies and soluble vaccines. The onlylimitation to the peptide or protein drug which may be utilized is oneof functionality.

As used herein, a “derivative” of a carbohydrate includes, for example,an acid form of a sugar, e.g. glucuronic acid; an amine of a sugar, e.g.galactosamine; a phosphate of a sugar, e.g. mannose-6-phosphate and thelike.

As used herein, “administering” and similar terms mean delivering thecomposition to the individual being treated such that the composition iscapable of being circulated systemically where the composition binds toa target cell and is taken up by endocytosis. Thus, the composition ispreferably administered systemically to the individual, typically bysubcutaneous, intramuscular, transdermal, intravenous, orintraperitoneal routes. Injectables for such use can be prepared inconventional forms, either as a liquid solution or suspension, or in asolid form that is suitable for preparation as a solution or suspensionin a liquid prior to injection, or as an emulsion. Suitable excipientsthat can be used for administration include, for example, water, saline,dextrose, glycerol, ethanol, and the like; and if desired, minor amountsof auxiliary substances such as wetting or emulsifying agents, buffers,and the like.

As used herein, “efficacy” and similar terms means disappearance oftumor or shrinkage of tumor in size or reduction in tumor density orincrease in lymphocyte count or increase in neutrophil count orimprovement in survival, or all of the above.

As used herein, “toxicity” is defined as any treatment related adverseeffects on clinical observation including but not limited to abnormalhematology or serum chemistry results or organ toxicity.

New cancer treatment strategies are focused on delivering macromoleculescarrying genetic information, rather than a therapeutic protein itself,allowing for the exogenously delivered genes to be expressed in thetumor environment. Methods that utilize non-viral gene delivery systemsare considered safer compared to viral delivery systems, but thepractical application of current polymeric systems has not beensatisfactory due to poor efficiency. A strategy has recently beendisclosed whereby the gene transfection efficiency of a low molecularweight PEI was enhanced by covalent attachment of cholesterol forming awater soluble lipopolymer (WSLP). See, Mol. Ther., 2001, 4, 130. IL-12gene transfer to solid tumors with WSLP was significantly better than bythe unmodified PEI and led to more significant tumor inhibition.

The present invention provides a novel polymeric system,PEG-PEI-Cholesterol (PPC), which differs from WSLP (PEI-Cholesterol) inthat it contains PEG moieties and yields significantly highertransfection efficiency in tumors (FIG. 1). The addition of PEG isdesigned to enhance the stability of the nucleic acid/polymer complexesin the biological milieu to circumvent for this deficiency in the priorart (WSLP). Furthermore, the addition of PEG chains allows for theincorporation of ligands on to the PPC chain to improve the tissueselectivity of delivery. For example, the cholesterol moiety which isdirectly linked to the PEI back bone in the prior art (WSLP) may beextended farther from the PEI backbone to create a more flexiblegeometry for cell receptor interaction. Controlling the number of PEGmolecules per unit of the PEI backbone is important to achieve optimalenhancement in transfection activity. As illustrated in FIG. 2, themagnitude of tumor gene transfer is dependent on the ratio between thedifferent PPC components, the PEG, PEI and cholesterol. A preferredrange of composition was a PEG:PEI molar ratio of 2-4 at a fixedcholesterol content. The optimal ratio between PEI and cholesterol was1:0.5 to 1:1. The ability of PPC to promote gene transfer into tumorswas examined with a therapeutic gene. Expression plasmid containingmouse IL-12 genes (pmIL-12) were complexed with PPC at a nitrogen (N) tophosphate (P) ratio (N:P ratio) of 11:1 and administered intratumorallyinto mice with solid 4T1 tumors or intraperitoneally in mice withperitoneal disseminated ovarian tumors.

In both tumor models IL-12 gene transfer was manifested by an increasein IL-12 levels (FIG. 3). In peritoneal tumor bearing micepost-treatment IL-12 levels rose within 24 hours and declined tobaseline level by 7 days. The kinetics of IL-12 action was closelyrelated to a rise in IFN-γ, a downstream mediator of IL-12 actions (FIG.4). The rise in IFN-γ levels was a bit delayed as expected and remainedelevated above baseline after 7 days. These data demonstratecompositions comprising IL-12 expression plasmids and PPC are capable ofmanifesting IL-12 gene transfer in different tumor types and bydifferent administration routes. The IL-12 gene transfer mediated bypmIL-12/PPC is therapeutically significant as it leads to a significantinhibition of tumor growth.

In mice with peritoneal disseminated ovarian tumors, intraperitonealadministration of pmIL-12/PPC complexes (N:P ratio 11:1) at a DNA doseof 10-250 μg significantly reduced the tumor burden (FIG. 5) andimproved survival (FIG. 6) in a dose dependent manner. The therapeuticeffect of pmIL-12/PPC (N:P ratio 11:1) was also observed in colorectalcancer. Intraperitoneal administration of 25 μg of pmIL-12/PPC complexesin mice with peritoneal disseminated colorectal cancer significantlyprolonged their survival compared to untreated animals (FIG. 7). Theanticancer efficacy of IL-12 gene transfer by pmIL-12/PPC was alsoobserved in solid tumors following intratumoral administration. FIG. 8illustrates the effects of intratumoral injection of pmIL-12/PPC on thegrowth of GL261 brain tumors. Treatment of intracranial implants ofmouse GL261 glioma by local delivery of pIL-12/PPC complexes (N:P ratio11:1) significantly enhanced survival. In mice with subcutaneouslyimplanted squamous cell carcinoma of the head and neck, intratumoraladministration of pmIL-12/PPC complexes once every week for four weeksproduced a significant inhibition of the rate of tumor growth (FIG. 9).The anticancer effect of pmIL-12/PPC complexes was also observed inovarian and breast tumors.

The composition of the present invention (nucleic acid and gene deliverypolymer) does not exert adverse side effects when administered in vivo.For example, no compound related deaths or clinical signs of toxicitywere associated with pmIL-12/PPC administration, intraperitoneally orsubcutaneously. pmIL-12/PPC was well tolerated in both male and femalemice at doses of 10, 50 and 250 μg per animal. Histopathologicexamination of animals in both the IP and SC dose groups demonstrated noevidence of systemic toxicity due to pmIL-12/PPC, mild inflammation wasnoted in organs located in or adjacent to the injection site but whichsubsided during a one month recovery period. These results demonstratethat nucleic acid/polymer compositions for treatment of cancer areeffective against a wide variety of cancers when given by differentmodes of administration and that repetitive in vivo delivery does notcause serious toxicity.

It is widely recognized that a single treatment strategy against canceris generally ineffective due to the multi-factorial nature of thisdisease. The benefit of combination of more than one drug to maximizeanticancer response is being increasingly recognized. Despiteencouraging preclinical data the clinical success of the chemo-chemocombinations or chemo-cytokine combinations examined to date have notbeen satisfactory due to the inherent toxicity of chemotherapeutic drugsand recombinant cytokine proteins. This warrants the need for a saferchemo-immunotherapy approach to curtail protein toxicity and improveefficacy. In the present invention we have combined a chemotherapeuticagent with gene delivery of an anticancer gene administered locally tothe tumor site to improve treatment safety and efficacy. Combining safeand efficient local delivery of an anticancer gene with a standardchemotherapeutic agent will enhance anticancer response and patientsurvival without augmenting toxicity. This combination therapy willreduce the chemotherapy dose and increase tumor sensitivity to thechemotherapy. In this invention, it is demonstrated that pharmaceuticalcompositions comprising an anticancer gene complexed with a cationicgene delivery polymer, and at least one adjunctive chemotherapeutic drugis more effective than gene therapy or chemotherapy treatmentadministered alone. Furthermore, the combination therapy is effectiveagainst a wide variety of tumors when given by different routes ofadministration and does not augment toxicity over individual therapies.

The anticancer response to combination therapy is demonstrated againstovarian tumors implanted into the peritoneal cavity. Intravenousadministration of paclitaxil (Taxol®) (8 mg/Kg) or intraperitonealadministration of mIL-12 plasmid (25-100 μg)/PPC complexes (N:P ratio11:1) produced tumor reduction and improved survival in tumor bearingmice. The pmIL-12/PPC treatment was more efficacious than the paclitaxeltreatment. The combination IL-12 gene and paclitaxel therapy producedgreater treatment response than the individual treatments(FIG. 10). Asimilar effect of the combination therapy on ovarian cancer was observedwhen IL-12 gene therapy was combined with another chemotherapeuticagent, gemcitabine (Gemzar®)(FIG. 11). The anti-cancer activity ofgemcitabine was significantly enhanced when used alongside with thepmIL-12/PPC treatment. The combination of IL-12 gene therapy with amixture of two chemotherapeutic agents was investigated. As shown inFIG. 12, combining IL-12 gene therapy with a carboplatin(Paraplatin®)/paclitaxel cocktail resulted in enhanced survival whencompared to either IL-12 therapy alone or chemotherapy alone. Additionof IL-12 gene therapy to a suboptimal dose of carboplatin/paclitaxelenhanced the therapeutic efficacy similar to that achieved with a highchemotherapy dose (FIG. 12) without augmenting the toxicity.

The improvement in anticancer response by combination therapy was alsoobserved in solid tumors. For example in subcutaneous squamous cellcarcinoma of the head and neck, intravenous administration of thechemotherapeutic agent cyclophosphamide (150 mg/kg) significantlyreduced the tumor growth but did not completely inhibit it (FIG. 13).Intratumoral injection of pmIL-12/PPC alone caused about 30% inhibitionof tumor growth. In contrast to the individual treatments, thecyclophosphamide plus pmIL-12/PPC combination treatment caused acomplete inhibition of tumor growth. The complete rejection ratedramatically increased from only 10% with cyclophosphamide to 55% withcyclophosphamide plus pmIL-12/PPC complexes. A single intratumoralinjection of a suboptimal dose (1.5 ug) of pmIL-12/PPC complexes inGL261 brain tumors did not significantly enhance the animal survivalrate. However, combination of this suboptimal dose of pmIL-12/PPC withthe chemotherapeutic agent BCNU (Gliadel® wafer) produced a significantenhancement in the survival rate (FIG. 14).

Cancer treatment with high dose chemotherapy is associated with serioustoxicity. To examine if the addition of IL-12/PPC to low dosechemotherapy augments treatment-related toxicity, peritonealdisseminated ovarian tumor-bearing mice were treated with threetreatment cycles (as compared to single treatment cycle) of IL-12/PPCand low dose chemotherapy and monitored for signs of toxicity. Directcomparison was made with animals treated with three cycles of high dosechemotherapy treatment. As shown in FIG. 15, 50% of high dosechemotherapy group died due to treatment related toxicity (i.e., beforereaching 40 gram) while none of IL-12/PPC+ low dose chemotherapy groupdied from treatment toxicity. These results demonstrate that thetoxicity of conventional chemotherapy (high dose) for cancer can besignificantly reduced by lowering the chemotherapy dose and adding saferand efficacious IL-12 gene therapy.

These data demonstrate the anticancer efficacy of the said compositionscomprising IL-12 plasmids and a novel gene delivery polymer, and itsaugmentation with a single or a mixture of chemotherapeutic agents. Thecombination approach provides a method by which the efficacy of asuboptimal dose of a chemotherapy regimen is enhanced without increasingtoxicity.

The following examples will enable those skilled in the art to moreclearly understand how to practice the present invention. It is to beunderstood that, while the invention has been described in conjunctionwith the preferred specific embodiments thereof, that which follows isintended to illustrate and not limit the scope of the invention. Otheraspects of the invention will be apparent to those skilled in the art towhich the invention pertains.

EXAMPLE 1

IL-12 Gene Transfer into Peritoneal Disseminated or Subcutaneous Tumorsby Local Administration of pIL-12/PPC Complexes

The ability of local delivery of pIL-12/PPC complexes to produce IL-12levels in subcutaneous and peritoneal disseminated tumor bearing micewas examined. For subcutaneous tumor studies, female BALB/c mice (7weeks, 14-18 grams) mice were injected subcutaneously (sc) in the leftand right flanks, with 1×10⁶ 4T1 cells each. After the tumors hadreached an approximate tumor size of 60mm³ they were injected withpmIL-12/PPC complexes containing 6 μg of DNA. The mice were sacrificed24 hours later and their tumors harvested for mIL12 analysis by ELISA.The mIL-12 levels in tumors 24 hours after the injection are shown inFIG. 3A.

For peritoneal tumor studies, female C57/BL6 mice were injectedintraperitoneally (ip) with 5×10⁶ ID8 cells in a volume of 500 μl. Thetreatments were started when the tumor burden (mouse weight) reachedapproximately 20 grams (˜21 days after injection of cells). The micewere injected intraperitoneally with a single dose of pmIL-12/PPC at a11:1 nitrogen (N) to phosphate (P) ratio (N:P ratio) in a volume of 500μl. Ascites fluid was removed from the tumor bearing animals 1, 2, 3 and7 days after the mice had been treated with pmIL-12/PPC. Levels ofmIL-12 and IFN-y were determined by ELISA and normalized to totalascitic fluid. The results show that significant levels of mIL-12 areseen in ascites fluid with peak levels achieved 1 day after treatmentwith levels falling to near base line by 7 days after treatment (FIG.3B). Levels of IFN-y are similarly seen to rise but peak levels aretemporarily delayed (day 3 peak) with respect to IL-12 levels and by 7days after treatment had fallen but were still significantly abovebaseline levels (FIG. 4).

EXAMPLE 2

Treatment of Peritoneal Disseminated Ovarian Tumors by intraperitonealAdministration of pIL-12/PPC Complexes

Mice were injected intraperitoneally with 5×10⁶ ID8 cells at a volume of500 μl. The treatments were started when the tumor burden (mouse weight)reached approximately 20 grams (˜21 days after injection of the cells).The mice were injected intraperitoneally with three weekly injections of10-250 μg of pIL-12 complexed with PPC at a 11:1 N:P ratio in a volumeof 500 μl. The mice were periodically weighed during the course of thestudy. Weight gain is predominantly caused by ascites accumulation whichprovides an indirect assessment of disease progression and tumor burden.The pmIL-12/PPC treatment produced a dose dependent inhibition of thetumor burden (FIG. 5) and prolongation of animal survival (FIG. 6).

EXAMPLE 3

Treatment of Peritoneal Disseminated Colorectal Tumors byIntraperitoneal Administration of pIL-12/PPC Complexes

Mice were injected intraperitoneally with 0.1×10⁶ CT26 cells in a volumeof 500 μl. The treatments were started 1 day after tumor implantation.The mice were injected intraperitoneally with five weekly injections of50 μg of pmIL-12 complexed with PPC or 25 μg of pIL-12 complexed withLPPC6 at an 11:1 N:P ratio in a volume of 500 μl. LPPC6 is a linearpolyethylenimine of 15 kD to which one molecule of mPEG and 6 moleculesof cholesterol are independently attached. As illustrated in FIG. 7, thepmIL-12/PPC and pmIL-12/LPPC6 treatment produced a significantimprovement in survival over untreated controls in this highlyaggressive tumor model.

EXAMPLE 4

Treatment of brain Cancer by Intratumoral Administration of pIL-12/PPCComplexes.

The effect of local delivery of pmIL-12/PPC complexes was examined in amouse glioma model. Tumors were implanted in the cerebral cortex of miceby intracranial injection of 1 ×10⁵ GL261 glioma cells together with theco-injection of pmIL-12/PPC complexes. The animals were monitored forany sign of neurotoxicity and autopsied, when possible, to confirm thatdeath was due to the intracranial tumor. Survival was plotted using aKaplan-Meier survival analysis. A single intracranial injection ofpmIL-12/PPC complexes administered at a dose range of 2.5-30 μg ofplasmid was well tolerated as no significant adverse effects wereobserved. A single injection of pmIL-12/PPC complexes at a dose of 15 ugplasmid produced a significant enhancement in animal survival (FIG. 8).

EXAMPLE 5

Treatment of Head & Neck Cancer by Intratumoral Administration ofpIL-12/PPC Complexes

The effect of local administration of pIL-12/PPC complexes on the growthof subcutaneously implanted squamous cell (SCCVII) carcinoma wasexamined. 4×10⁵ squamous carcinoma cells in 100 μl were implanted sc onthe right flank of female Female CH3 mice (6-9 weeks, 17-22 grams) ThemIL-12 plasmid was complexed with PPC at a 11:1 N:P ratio andadministered locally into the tumors at a DNA dose of 25 μg in aninjection volume of 50 μl once every week for four weeks starting ˜11days after tumor implantation. Treatment groups of 12 mice were used andtumor growth was monitored twice per week using calliper measurement. Asshown in FIG. 9, intratumoral administration of pmIL-12/PPC complexesproduced a partial but significant inhibition of tumor growth.

EXAMPLE 6

pIL-12/PPC Plus Paclitaxel Combination Therapy for the Treatment ofPeritoneal Disseminated Ovarian Tumors

Intraperitoneal IL-12 gene therapy was combined with paclitaxelchemotherapy to enhance the therapeutic response to disseminated ovariantumors in mice. The mice were injected intraperitoneally with 5×10⁶ ID8cells in a volume of 500 μl. The treatments were started when tumorburden (mouse weight) reached approximately 20 grams (˜21 days afterinjection of cells). The mice were injected intraperitoneally with 25 μgof pmIL-12 complexed with PPC at a 11:1 N:P ratio in a volume of 500 μl.The gene treatment was repeated after 7 days constituting a total of twoinjections (Day 1, 8) per the study. Paclitaxel (Taxol®) wasadministered only once (Day 0) by intravenous injection at a dose of 8mg/kg dose in an injection volume of 250 μL. For combination therapy,both gene therapy and chemotherapy treatments were given as describedabove. Animals were periodically weighed to assess the effect of genetreatment on tumor burden. Intraperitoneal injection of pmIL-12/PPCcomplexes alone produced significant reduction of peritoneal tumorburden. The inhibition of tumor burden by pmIL-12/PPC complexes wasslightly higher than that of paclitaxel. Addition of IL-12 gene therapyto paclitaxel resulted in an improvement in paclitaxil action on tumorburden and survival (FIG. 10).

EXAMPLE 7

pIL-12/PPC Plus Gemcitabine Combination Therapy for the treatment ofPeritoneal Disseminated Ovarian Cancer

The efficacy of combining IL-12 gene therapy with Gemcitabine (Gemzar®)was evaluated. Gemcitabine belongs to a general group of chemotherapydrugs known as antimetabolites. It is used to treat pancreatic cancer,breast cancer (along with paclitaxel), and lung cancer (along withcisplatin), and is currently being evaluated clinically for use againstovarian cancer. For this study, mice (C57BL/6) were injectedintraperitoneally with 2.5×10⁶ ID8 cells in a volume of 500 μl to inducedisseminated tumor formation. At 14 days after tumor implantationgemcitabine was administered intraperitoneally at a dose of 150 mg/kg ina volume of 250 μl. Treatment was repeated weekly for a total of 4treatments. Starting 17 days after tumor implantation, selected groupsof mice were treated intraperitoneally with 25 μg of IL-12 plasmidscomplexed with PPC at a 11:1 N:P ratio in a volume of 500 μl. Plasmidadministration was repeated weekly for a total of four treatments.Combination treatment of IL-12 gene therapy and gemcitabine chemotherapysignificantly improved survival compared to either monotherapy alone(FIG. 11).

EXAMPLE 8

PIL-12/PPC Plus Carboplatin/Paclitaxel Combination therapy for thetreatment of Peritoneal Disseminated Ovarian Cancer

Frontline chemotherapy for ovarian cancer continues to be a platinumagent (carboplatin, cisplatin) and paclitaxel. Thus, we were interestedin evaluating the use of IL-12 gene therapy in combination with acarboplatin/paclitaxel chemotherapy regimen. Mice (C57BL/6) wereinjected intraperitoneally with 2.5×10⁶ ID8 cells in a volume of 500 μl.Chemotherapy treatment was started 15days after tumor implantation.Carboplatin (Paraplatin®) administration was at either 40 mg/kg ip in250 ml (high dose) or 15 mg/kg in 250 μl (low dose) and paclitaxel(Taxol®) administration was given at either 8 mg/kg ip in 250 μl (highdose) or 3 mg/kg intraperitoneally in 250 ml (low dose). Carboplatin wasgive once weekly for a total of 4 treatments and paclitaxel was givenq2w for a total of two treatments. When carboplatin and paclitaxel weregiven on the same day the paclitaxel was administered first and thencarboplatin two hours later. Starting 18 days after tumor implantation,mice in selected groups were treated intraperitoneally with 25 μg ofIL-12 plasmid complexed with PPC at a 11:1 N:P ratio in a volume of 50082 l. Plasmid administration was repeated weekly for a total of fourtreatments. Following the end of the treatment regimen the animals weremonitored for survival. The results indicate that both the IL-12 genetherapy and the low dose carboplatin/paclitaxel chemotherapy producedsimilar survival outcomes (FIG. 12). In contrast when low dosechemotherapy was combined with IL-12 gene therapy the efficacy improvedto a level that was nearly identical to that of the high dosechemotherapy treatment regimen. It would be advantageous to be able touse IL-12 gene therapy in combination with low dose chemotherapy inorder to maintain therapeutic efficacy while using lower chemotherapydoses in order to minimize toxicities. This would potentially allowpatients to remain on chemotherapy treatment regimens for prolongedperiods of time offering the chance for a greatly enhanced therapeuticresponse.

EXAMPLE 9

pIL-12/PPC Plus Cyclophosphamide Combination Therapy for the Treatmentof Head and Neck Cancer

Intratumoral IL-12 gene therapy was combined with cyclophosphamide(Cytoxan® chemotherapy to enhance the therapeutic response in head andneck cancer. 4×10⁵ squamous carcinoma cells (SCCVII) in 100 μl wereimplanted sc on the right flank of female Female CH3 mice (6-9 weeks,17-22 grams). Five days prior to cyclophosphamide treatment(approximately 11 days after tumor implant) mIL-12 plasmids werecomplexed with PPC at a 11:1 N:P ratio and administered locally into thetumors at a DNA dose of 25 μg in an injection volume of 50 μl once everyweek for four weeks. Cyclophosphamide therapy was administeredintravenously at a dose of 200 mg/kg in an injection volume of 125 μlalone or in combination with pIL-12 gene therapy. Cyclophosphamidetreatment was repeated after 14 days constituting a total of twoinjections per study. For combination therapy both gene therapy andchemotherapy treatment were given as described above. Treatment groupsof 12 mice were used and tumor growth was monitored twice per week usingcalliper measurement. As shown in FIG. 13, intratumoral administrationof pmIL-12/PPC complexes or intravenous injection of cyclophosphamidealone produced only a partial inhibition of tumor growth while theircombination produced complete inhibition. There was a higher percentageof animals treated with combination therapy that completely rejected thetumor (55%) as opposed to the animals treated with chemotherapy alone(10%).

EXAMPLE 10

Treatment of Brain Cancer by Intratumoral pIL-12/PPC and BCNUCombination Therapy.

The effect of local delivery of pmIL-12/PPC complexes alone or incombination with BCNU (Gliadel®) was examined in a mouse glioma model.Gliadel® wafer is a polymeric formulation of carmustine or BCNU, achemotherapeutic agent of the nitrosourea family. Tumors were implantedin the cerebral cortex of mice by intracranial injection of 1×10⁵ GL261glioma cells together with the co-injection of pmIL-12/PPC complexes.Five days after tumor implantation, Gliadel® containing 10% BCNU wasimplanted below the inner table of the parietal bone. Animals weremonitored for any sign of neurotoxicity and autopsied, when possible, toconfirm that death was due to intracranial tumor. Survival was plottedusing a Kaplan-Meier survival analysis. A single intracranial injectionof pmIL-12/PPC complexes administered in a dose range of 2.5-30 μg ofplasmid was well tolerated as no significant adverse effects wereobserved. A single injection of pmIL-12/PPC complexes administered at a1.5 ug plasmid dose did not increase the survival rate. However,combination of this suboptimal dose of pmIL-12/PPC with BCNUsignificantly enhanced survival (FIG. 14). The enhancement in survivalfrom combination therapy was higher than historically achieved with BCNUalone in this model (data not shown).

EXAMPLE 11

Comparison of toxicity of IL-12/PPC Plus Low Dose Carboplatin/PaclitaxelCombination Therapy and High Dose Carboplatin/Paclitaxel CombinationTherapy.

It has been previously demonstrated by the applicants that combiningIL-12/PPC with low dose carboplatin (15 mg/kg) and paclitaxel (3 mg/kg)therapy produces anticancer efficacy similar to high dose carboplatin(40 mg/kg) and paclitaxel (8 mg/kg) chemotherapy (Example 8, FIG. 12).In this example, it is examined if IL-12/PPC plus low dose combinationchemotherapy is less toxic than the high dose chemotherapy. Mice bearingperitoneal disseminated ovarian tumors were administered with threetreatment cycles of IL-12/PPC+ low dose chemotherapy or high dosechemotherapy as compared to only one treatment cycle used in theprevious examples. Animal mortality occurring prior to reaching the 40gram body weight cut-off (criterion for sacrificing animals due todisease advancement) and not showing significant tumor burden atnecropsy were considered treatment related. Mice (C57BL/6) were injectedintraperitoneally with 2.5×10⁶ ID8 cells in a volume of 500 μl.Chemotherapy treatment was started 15days after tumor implantation.Carboplatin (Paraplatin®) administration was at either 40 mg/kg ip in250 ml (high dose) or 15 mg/kg in 250 μl (low dose) and paclitaxel(Taxol®) administration was given at either 8 mg/kg ip in 250 μl (highdose) or 3 mg/kg intraperitoneally in 250 ml (low dose). Carboplatin wasgive once weekly for a total of 4 treatments and paclitaxel was givenq2w for a total of two treatments. On treatment days paclitaxel wasadministered first and then carboplatin two hours later. Starting 18days after tumor implantation, mice in selected groups were treatedintraperitoneally with 100 μg of IL-12 plasmid complexed with PPC at a11:1 N:P ratio in a volume of 500 μl. Plasmid administration wasrepeated weekly for a total of four treatments. The entire treatmentcycle was repeated three times (12 weeks total), and the animals weremonitored for survival. As shown in FIG. 15, 30% of high dosechemotherapy group died due to treatment related toxicity (i.e., beforereaching 40 gram) compared to 0% treatment related death in IL-12/PPC+low dose chemotherapy group, in the low dose chemotherapy group or theIL-12/PPC only treatment group. These results demonstrate that incomparison to a high dose chemotherapy regimen, combining IL-12/PPC withlow dose chemotherapy produces relatively fewer treatment related deathsbut produces similar anticancer efficacy (FIG. 12).

It is to be understood that the above-described embodiments are onlyillustrative of the application of the principles of the presentinvention. Numerous modifications and alternative embodiments can bederived without departing from the spirit and scope of the presentinvention and the appended claims are intended to cover suchmodifications and arrangements. Thus, while the present invention hasbeen shown in the drawings and is fully described above withparticularity and detail in connection with what is presently deemed tobe the most practical and preferred embodiment(s) of the invention, itwill be apparent to those of ordinary skill in the art that numerousmodifications can be made without departing from the principles andconcepts of the invention.

1. A pharmaceutical composition comprising a nucleic acid, a genedelivery polymer and at least one pharmaceutical agent for the treatmentof cancer or hyperproliferative disorders.
 2. The pharmaceuticalcomposition of claim 1, wherein the nucleic acid is selected from thegroup consisting of plasmid DNA, siRNA, sense RNA, anti-sense RNA andribozyme.
 3. The pharmaceutical composition of claim 1, wherein the genedelivery polymer is a lipopolymer comprising a polyethylenimine (PEI)backbone covalently linked with a lipid and a polyethylene glycol, andat least one pharmaceutical agent for the treatment of cancer orhyperproliferative disorders.
 4. The pharmaceutical composition of claim1, wherein the pharmaceutical agent is selected from the groupconsisting of chemotherapeutic drugs, anti-angiogenic agents,anti-cancer peptides, monoclonal antibodies and mixtures thereof for thetreatment of cancer or hyperproliferative disorders.
 5. The compositionof claim 1, wherein the pharmaceutical agent is a chemotherapeutic agentor an anticancer agent selected from the group consisting of adriamycin,bleomycin, cisplatin, carboplatin, doxorubicin, 5-fluorouracil,paclitaxel, topotecan, carmustine, gemcitabine or any relatedchemotherapeutic agent of the same class and any combinations thereof.6. The composition of claim 3, wherein the pharmaceutical agent is achemotherapeutic agent or an anticancer agent selected from the groupconsisting of adriamycin, bleomycin, cisplatin, carboplatin,doxorubicin, 5-fluorouracil, paclitaxel, topotecan, carmustine,gemcitabine or any related chemotherapeutic agent of the same class andany combinations thereof.
 7. A method for inhibiting the growth andmetastasis of tumor cells and improving survival in mammals by in vivoadministration of a pharmaceutical composition comprising a nucleicacid, a gene delivery polymer and at least one pharmaceutical agent forthe treatment of cancer or hyperproliferative disorders.
 8. The methodof claim 7, wherein the gene delivery polymer is a lipopolymercomprising a polyethylenimine (PEI) backbone covalently linked with alipid and a polyethylene glycol.
 9. The method of claim 7, wherein thenucleic acid is selected from the group consisting of plasmid DNA,siRNA, sense RNA, anti-sense RNA and ribozyme.
 10. The method of claim7, wherein the pharmaceutical agent is selected from the groupconsisting of chemotherapeutic drugs, anti-angiogenic agents, anticancerpeptides and monoclonal antibodies for the treatment of cancer orhyperproliferative disorders.
 11. The method of claim 7, wherein thetumor is localized in ovary, uterus, stomach, colon, rectum, bone,blood, intestine, pancreas, breast, head, neck, lungs, spleen, liver,kidney, brain, thyroid, prostate, urinary bladder, thyroid, skin,abdominal cavity, thoracic cavity or any combination thereof.
 12. Themethod of claim 7, wherein the said nucleic acid composition isdelivered by intraperitoneal, intratumoral, intravenous, intra-arterial,intratracheal, intrahepaticportal, oral, intracranial administration orany combination thereof.
 13. The method of claim 7, wherein the saidnucleic acid is a DNA plasmid encoding for a protein selected from thegroup consisting of interleukin-2, interleukin-4, interleukin-7,interleukin-12, interleukin-15, interferon-α, interferon-β,interferon-γ, colony stimulating factor, granulocyte-macrophage colonystimulating factor, anti-angiogenic agents, thymidine kinase, p53, IP10,p16, TNF-α, Fas-ligand, tumor antigens, viral antigens, bacterialantigens or any combination thereof.
 14. The method of claim 7, whereinthe said nucleic acid is a DNA plasmid encoding for interleukin-12. 15.The method of claim 7, wherein the said nucleic acid is a single DNAplasmid encoding for more than one protein selected in any combinationfrom the group consisting of interleukin-2, interleukin-4,interleukin-7, interleukin-12, interleukin-15, interferon-α,interferon-β, interferon-γ, colony stimulating factor,granulocyte-macrophage colony stimulating factor, anti-angiogenicagents, thymidine kinase, p53, IP10, p16, TNF-α, Fas-ligand, tumorantigens, viral antigens and bacterial antigens.
 16. The method of claim7, wherein the said nucleic acid is a DNA plasmid encoding for shorthairpin RNA designed to inhibit expression of a protein required fortumor growth and metastases.
 17. The method of claim 7, wherein the saidnucleic acid is an RNA selected from the group consisting of a siRNA,sense RNA, antisense RNA, a ribozyme and any combination thereofdesigned to inhibit expression of a protein required for tumor growthand metastases.
 18. The method of claim 7, wherein the nucleic acid is asingle DNA plasmid encoding for a short hairpin RNA and a proteinselected from the group consisting of interleukin-2, interleukin-4,interleukin-7, interleukin-12, interleukin-15, interferon-α,interferon-β, interferon-γ, colony stimulating factor,granulocyte-macrophage stimulating factor, anti-angiogenic agents,thymidine kinase, p53, IP10, p16, TNF-α, eNOS, iNOS, Fas-ligand, tumorantigens, viral antigens, bacterial antigens and any combinationthereof.
 19. The method of claim 7, wherein the nucleic acid is an RNAselected from the group consisting of an siRNA, sense RNA, antisenseRNA, or a ribozyme and a plasmid DNA encoding for a protein selectedfrom the group consisting of interleukin-2, interleukin-4,interleukin-7, interleukin-12, interleukin-15, interferon-α,interferon-β, interferon-γ, colony stimulating factor,granulocyte-macrophage colony stimulating factor, anti-angiogenicagents, thymidine kinase, p53, IP10, p16, TNF-α, eNOS, iNOS, Fas-ligand,tumor antigens, viral antigens, bacterial antigens or any combinationthereof.
 20. The method of claim 8, wherein the polyethylenimine has alinear or branch configuration with a molecular weight of 100-500,000Daltons.
 21. The method of claim 8, wherein both the lipid and thepolyethylene glycol are directly attached to the PEI backbone bycovalent bonds.
 22. The method of claim 8, wherein the lipid is attachedto the PEI backbone through a polyethylene glycol spacer.
 23. The methodof claim 8, wherein the polyethylene glycol has molecular weight ofbetween 50 to 20,000 Daltons.
 24. The method of claim 8, wherein thelipid is a cholesterol, a cholesterol derivative, a C₁₂ to C₁₈ fattyacid or a fatty acid derivative.
 25. The method of claim 8, wherein themolar ratio of polyethylene glycol to PEI is within a range of 0.1:1 to500:1.
 26. The method of claim 8, wherein molar ratio of the lipid toPEI is within a range of 0.1:1 to 500:1.
 27. The composition of claim 8,wherein polyethylenimine further comprises a targeting moiety, whereinthe targeting moiety is directly attached to the polyethyleniminebackbone or is attached through a polyethylene glycol linker.
 28. Thecomposition of claim 27, wherein the targeting moiety is selected fromthe group consisting of transferrin, asialoglycoprotein, antibodies,antibody fragments, low density lipoproteins, interleukins, GM-CSF,G-CSF, M-CSF, stem cell factors, erythropoietin, epidermal growth factor(EGF), insulin, asialoorosomucoid, mannose-6-phosphate, mannose,Lewis^(X) and sialyl Lewis^(X), N-acetyllactosamine, folate, galactose,lactose, and thrombomodulin, fusogenic agents such as polymixin B andhemagglutinin HA2, lysosomotrophic agents, nucleus localization signals(NLS) and any combination thereof.
 29. The composition of claim 27,wherein the molar ratio of the lipopolymer and targeting moiety iswithin a range of 1:0.1 to 1:100.
 30. The method of claim 8, wherein thesaid nucleic acid is complexed with the said lipopolymer at nitrogenmoles in the lipopolymer to phosphate moles in the DNA at a molar ratioof 0.1:100 to 100:1.
 31. The method of claim 27, wherein the saidnucleic acid is complexed with the said lipopolymer at nitrogen moles inthe lipopolymer to phosphate moles in the DNA at a molar ratio of0.1:100 to 100:1.
 32. The method of claim 7, wherein the pharmacologicalagent is a chemotherapeutic agent or an anticancer agent selected fromthe group consisting of adriamycin, bleomycin, cisplatin, carboplatin,doxorubicin, 5-fluorouracil, paclitaxel, topotecan, carmustine,gemcitabine or any related chemotherapeutic agents of the same class andany combinations thereof.
 33. The method of claim 27, wherein thepharmacological agent is a chemotherapeutic agent or an anticancer agentselected from the group consisting of adriamycin, bleomycin, cisplatin,carboplatin, doxorubicin, 5-fluorouracil, paclitaxel, topotecan,carmustine, gemcitabine or any related chemotherapeutic agents of thesame class and any combinations thereof.
 34. The method of claim 7,wherein the pharmacological agent is an anti-angiogenic agent selectedfrom the group consisting of monoclonal antibodies, thalidomide,angiostatin, endostatin, epidermal growth factor receptor inhibitors,matrix metalloproteinase inhibitors and any combinations thereof. 35.The method of claim 27, wherein the pharmacological agent is ananti-angiogenic agent selected from the group consisting of monoclonalantibodies, thalidomide, angiostatin, endostatin, epidermal growthfactor receptor inhibitors, matrix metalloproteinase inhibitors and anycombinations thereof.
 36. The method of claim 7, wherein thepharmaceutical agent is administered by intravenous, oral orintraperitoneal administration.
 37. The method of claim 7, wherein thenucleic acid and gene delivery polymer is given before theadministration of the pharmaceutical agent.
 38. The method of claim 7,wherein the said nucleic acid and polymer is given after theadministration of the pharmaceutical agent.
 39. The method of claim 7,wherein the said combination treatment is more efficacious than theindividual treatments.
 40. The method of claim 7, wherein the saidcombination treatment is equal to or less toxic than the individualtreatments.
 41. The method of claim 7, wherein the said combinationtreatment at an optimal dose of the nucleic acid and a suboptimal doseof the pharmaceutical agent gives a higher or equal efficacy than thatof the optimal dose of the pharmaceutical agent.
 42. The method of claim7, wherein the said combination treatment comprising an optimal dose ofthe said nucleic acid and a suboptimal dose of the pharmaceutical agentis less toxic than that of the optimal dose of pharmaceutical agent. 43.The pharmaceutical composition of claim 4, wherein the pharmaceuticalagent is a polypeptide selected from the group consisting ofinterleukin-2, interleukin-4, interleukin-7, interleukin-12, IL-15,interferon-α, interferon-β, interferon-γ, colony stimulating factor,granulocyte-macrophage colony stimulating factor, anti-angiogenicagents, TNF-α, eNOS, iNOS, IP10, p16, bacterial antigens, viralantigens, tumor antigens and any combination thereof.
 44. Thepharmaceutical composition of claim 7, wherein the pharmaceutical agentis an antibody.
 45. The pharmaceutical composition of claim 7, whereinthe pharmaceutical agent is an anti-cancer antibody selected from thegroup consisting of CD20 antibody, HER2/neu antibody, anti-VEGFantibody, epidermal growth factor receptor antibody and radioisotopicconjugates thereof.
 46. The method of claim 7, wherein the saidpharmaceutical agent is a polypeptide selected from the group consistingof interleukin-2, interleukin-4, interleukin-7, interleukin-12, IL-15,interferon-α, interferon-β, interferon-γ, colony stimulating factor,granulocyte-macrophage colony stimulating factor, anti-angiogenicagents, IP10, p16, eNOS, iNOS, TNF-α, bacterial antigens, viralantigens, tumor antigens and any combination thereof.
 47. The method ofclaim 7, wherein the gene delivery polymer is selected from the groupconsisting of any chemically modified polyethylenimine,polypropylenimine, aminoglycoside-polyamine,dideoxy-diamino-b-cyclodextrin, spermine, spermidine,poly(2-dimethylamino)ethyl methacrylate, poly(lysine), cationizedgelatin, dendrimers, chitosan and any combination thereof.
 48. Themethod of claim 7, wherein the gene delivery polymer is a non-condensingpolymer selected from the group consisting of polyvinyl pyrollidone,polyvinyl alcohol, poloxamers, polyglutamate, gelatin,polyphosphoesters, silk-elastin-like hydrogels, agarose hydrogels, lipidmicrotubules, poly(lactide-co-glycolide), polyethyleneglycol-linkedpoly(lactide-co-glycolide) and any combination thereof.